Mineralys Therapeutics (MLYS) Free Cash Flow (2022 - 2026)

Mineralys Therapeutics has disclosed Free Cash Flow across 5 years of filings, most recently posting -$39.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$39.5 million, up 13.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$136.4 million (up 29.21% YoY), and the FY2025 annual result was -$142.4 million, up 14.41% from the prior year.
• Free Cash Flow came in at -$39.5 million for Q1 2026 at Mineralys Therapeutics, down from -$37.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$5.5 million in Q2 2022 to a low of -$66.8 million in Q4 2024.
• The 5-year median for Free Cash Flow is -$28.8 million (2025), against an average of -$27.0 million.
• Across the five-year window, Free Cash Flow sank 272.76% in 2023 and soared 43.25% in 2025, its largest moves.
• Mineralys Therapeutics' Free Cash Flow stood at -$10.2 million in 2022, then slumped by 184.52% to -$29.0 million in 2023, then slumped by 130.64% to -$66.8 million in 2024, then jumped by 43.25% to -$37.9 million in 2025, then retreated by 4.06% to -$39.5 million in 2026.
• The last three Free Cash Flow figures came in at -$39.5 million (Q1 2026), -$37.9 million (Q4 2025), and -$28.8 million (Q3 2025), per Business Quant data.